Active	Status	Sponsor type	Region	Phase	Filter
63 Active 124 Inactive 187 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ge, Jian
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL	Recruiting	3	476	RoW	Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo	InnoCare Pharma Inc.	Mantle Cell Lymphoma	06/31	06/32
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Recruiting	2/3	226	RoW	ICP-248, Orelabrutinib	Beijing InnoCare Pharma Tech Co., Ltd.	Hematologic Malignancies	11/30	07/31
NCT05698147: Selinexor in Combination With MTX+Ritu to Treat R/R CNSL	Recruiting	1/2	30	RoW	Selinexor, ATG-010, Rituximab, RiTUXimab Injection, Methotrexate, MTX	Tong Chen, MD, Antengene Corporation	Central Nervous System Lymphoma	06/26	12/26
ICP-CL-01201, NCT05728658: The Study of ICP-248 in Patients With Mature B-cell Malignancies	Recruiting	1	105	RoW	ICP-248	Beijing InnoCare Pharma Tech Co., Ltd.	Hematological Malignancies	08/24	10/26
Lin, Mingkai
NCT05130554: XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma	Active, not recruiting	N/A	20	RoW	XEN45 gel stent implantation, XEN	Zhongshan Ophthalmic Center, Sun Yat-sen University, Allergan	Glaucoma, Glaucoma, Open-Angle, Surgery	06/22	09/22
Zuo, Chengguo
No trials found
Yang, Yahan
No trials found
Wang, Dingqiao O
No trials found
Zheng, Weixin
No trials found
Weirong, Chen
No trials found
Li, Ruiyang
No trials found
Wang, Qiwei
No trials found
Huang, Zhihong O
No trials found
Shi, Huanyang
No trials found